Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide in Non-variceal GI Bleeding in ICU
NCT06062719Phase 3Unknown
- Sponsor
- National Hepatology and Tropical Medicine Research Institute
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Octreotide long-acting injection in gastrointestinal bleeding (2 arms), sponsored by National Hepatology and Tropical Medicine Research Institute. Primary endpoint: Incidence of rebleeding at 7 days. Status: unknown.
02
Drugs
Octreotide long-acting injection
03
Conditions
gastrointestinal bleeding
Beyond the preview
Go deeper on NCT06062719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062719.